Enfortumab vedotin plus pembrolizumab followed by surgery showed high complete response rates in advanced urothelial cancer.

The findings suggest that enfortumab vedotin, especially combined with pembrolizumab, offers promising beneficial outcomes in metastatic urothelial carcinoma treatment,” researchers wrote.

Since September 2024, enfortumab vedotin in combination with pembrolizumab has also been approved for the first-line treatment of unresectable or metastatic urothelial carcinoma. The German ...

Since September 2024, enfortumab vedotin in combination with pembrolizumab has also been approved for the first-line treatment of unresectable or metastatic urothelial carcinoma. The German ...

Bicycle Therapeutics targets innovative cancer treatments with potential, like zelenectide pevedotin. Read here for an ...

Pfizer advances bold vision for future of cancer care at the ASCO 2025 annual meeting: New York Friday, April 25, 2025, 10:00 Hrs [IST] Pfizer Inc. will showcase data across its p ...

Bladder cancer stands as one of the main factors leading to cancer-related disability and death among patients of the elder age group. Some patients are unable to use Cisplatin-based chemotherapy ...

Enfortumab vedotin plus pembrolizumab was associated with improvements in response, disease control, and survival when compared to chemotherapy. Results of a meta-analysis suggest that enfortumab ...

Additionally, new exploratory analyses will be presented from the pivotal EV-302 trial with PADCEV® (enfortumab vedotin) in combination with KEYTRUDA® (pembrolizumab) in patients with previously ...